Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank100
3Y CAGR+39.9%
5Y CAGR+64.8%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
+39.9%/yr
Annual compound
5Y CAGR
+64.8%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
12.2x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $644.59M | +37.6% |
| 2024 | $468.37M | +25.5% |
| 2023 | $373.28M | +58.6% |
| 2022 | $235.30M | -21.0% |
| 2021 | $297.98M | +462.8% |
| 2020 | $52.95M | +159.2% |
| 2019 | $-89.46M | -65.2% |
| 2018 | $-54.16M | -140.8% |
| 2017 | $132.70M | +348.0% |
| 2016 | $-53.52M | - |